Akebia Therapeutics (Nasdaq: AKBA) granted inducement stock options to five newly hired employees on February 27, 2026, totaling 46,200 shares.
The options carry an exercise price of $1.31 (equal to closing price on the grant date), vest over four years (25% after one year, then quarterly), and have a 10-year term under Akebia's inducement award program.
Loading...
Loading translation...
Positive
None.
Negative
None.
Key Figures
New hires:5 employeesOption shares:46,200 sharesExercise price:$1.31 per share+5 more
8 metrics
New hires5 employeesInducement stock option grants to new employees
Option shares46,200 sharesAggregate common stock underlying new inducement options
Exercise price$1.31 per shareEqual to AKBA closing price on February 27, 2026 grant date
Vesting period4 yearsStock options vest over four years, service‑based
Initial cliff vest25% of sharesVest on first anniversary of grant date
Remaining vesting75% of sharesVest quarterly after first anniversary, service‑based
Option term10 yearsTerm of each inducement stock option grant
Grant dateFebruary 27, 2026Date inducement options were granted
Market Reality Check
Price:$1.26Vol:Volume 6,456,855 is 1.66x...
high vol
$1.26Last Close
VolumeVolume 6,456,855 is 1.66x the 20-day average of 3,886,917, indicating elevated trading ahead of this routine grant filing.high
TechnicalShares trade below the 200-day MA, at $1.31 vs 200-day MA of $2.55, and sit 67.88% under the 52-week high of $4.0787.
Peers on Argus
AKBA slipped 0.76% while key peers were mixed: AQST -0.74%, ORGO -13.94%, SIGA -...
AKBA slipped 0.76% while key peers were mixed: AQST -0.74%, ORGO -13.94%, SIGA -1.22%, but ESPR +0.60% and DVAX +0.06%. Moves do not indicate a unified sector trend.
Vafseo access expansion, large Phase IV trials, and rare kidney pipeline plans.
Pattern Detected
Recent news often aligned with price moves; notably, a positive earnings report saw a 9.09% gain, while one broadly positive corporate update drew a -7.89% divergence.
Recent Company History
Over recent months, Akebia reported stronger fundamentals and ongoing pipeline progress. Q4 and full‑year 2025 results on Feb 26, 2026 showed higher revenues and were followed by a 9.09% gain. Earlier, a Jan 12, 2026 corporate update highlighted Vafseo commercial expansion, large Phase IV trials, and multiple Phase 2 programs, yet the stock fell 7.89%. The company also announced inducement option grants and conference participation, with modest price reactions, framing today’s new‑hire option grants as part of a continuing equity‑compensation pattern.
Market Pulse Summary
This announcement details standard hiring-related equity compensation, granting options on 46,200 sh...
Analysis
This announcement details standard hiring-related equity compensation, granting options on 46,200 shares at an exercise price of $1.31 under Nasdaq Listing Rule 5635(c)(4). The options vest over four years with a 10‑year term, reinforcing Akebia’s use of equity to attract talent. Set against recent strong 2025 results and ongoing pipeline work, these grants extend an existing pattern of stock-based compensation, which investors can monitor alongside future filings and operational milestones.
"The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
stock optionsfinancial
"granted five newly-hired employees options to purchase an aggregate of 46,200 shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise pricefinancial
"The options have an exercise price of $1.31 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestingfinancial
"The stock options vest over four years, with 25% of the shares vesting on the first anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
inducement award programfinancial
"subject to the terms and conditions of Akebia’s inducement award program"
A program where a company gives new hires or key contributors stock, stock options, or cash bonuses to persuade them to join or stay, like a signing bonus but paid in company shares or equity-based pay. Investors care because these awards can dilute existing share ownership, change executive incentives and company costs, and signal how aggressively the company is investing in talent to drive future performance.
AI-generated analysis. Not financial advice.
CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 46,200 shares of Akebia’s common stock on February 27, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $1.31 per share, which is equal to the closing price of Akebia’s common stock on the grant date. The stock options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with Akebia. Each stock option has a 10-year term and is subject to the terms and conditions of Akebia’s inducement award program and a stock option agreement covering the grant.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
What did Akebia (AKBA) announce about inducement grants on March 2, 2026?
Akebia granted options for an aggregate of 46,200 shares to five new hires on February 27, 2026. According to the company, the grants comply with Nasdaq Listing Rule 5635(c)(4) and are intended to induce employment.
What is the exercise price and term of the AKBA inducement stock options?
The options have an exercise price of $1.31 per share, equal to the closing price on the grant date. According to the company, each option carries a 10-year term and is subject to the inducement award program terms.
How do the AKBA inducement options vest for new employees?
Options vest over four years: 25% vests on the first anniversary, then the remaining 75% vests quarterly. According to the company, vesting is subject to each new employee's continued service with Akebia.
Why did Akebia use Nasdaq Listing Rule 5635(c)(4) for these AKBA grants?
Akebia used Rule 5635(c)(4) to grant inducement awards to new hires outside its shareholder-approved equity plan. According to the company, the grants were made as an inducement material to employment under that Nasdaq rule.
Will the AKBA inducement grants dilute existing shareholders?
The grants represent authorization to purchase 46,200 common shares, which could dilute outstanding shares if exercised. According to the company, exercises will follow the exercise price and standard terms of the inducement agreements.
